Neoplasia: Mechanisms of Carcinogenesis and Classification

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Neoplasia arises from heritable genetic and epigenetic alterations in genes controlling cell proliferation, survival, and differentiation, including proto-oncogenes (gain-of-function) and tumor suppressor genes (loss-of-function). Carcinogenesis progresses through initiation (initial genetic alteration), promotion (expansion of initiated cells), and progression (accumulation of malignant characteristics).
• Benign neoplasms are circumscribed and non-invasive, while malignant neoplasms are invasive and possess metastatic potential; histologic features like cellular atypia, increased mitotic activity, and necrosis support malignancy, but biologic behavior is the definitive distinction.
• Histologic classification identifies the cell of origin (carcinoma, sarcoma, lymphoma, etc.), with subclassification based on differentiation and architecture, often aided by immunohistochemistry (IHC) using lineage-specific markers when morphology is ambiguous.
• Histologic grading, assessing differentiation, mitotic count, and necrosis, correlates with clinical outcome and guides treatment; standardized consensus recommendations, such as those from the Oncology-Pathology Working Group (OPWG), are crucial for consistent interpretation across tumor types and species.
• Diagnostic accuracy relies on adequate specimen handling, including proper fixation and sectioning, and the pathologist evaluates architecture, cytology, stromal reaction, invasion patterns, and mitotic count, with margin assessment critical for surgical planning and prognosis.
• Ancillary testing, including IHC (e.g., KIT in mast cell tumors for prognostic/predictive value) and flow cytometry (for lymphoma immunophenotyping), complements histomorphology, but should not replace fundamental histologic assessment, especially when resources are limited.

Neoplasia represents a fundamental disturbance of cell growth control, in which cells acquire heritable alterations that permit progressive, unregulated proliferation. This article provides the conceptual foundation for understanding how neoplasms arise, how they are classified, and how histologic features inform clinical behavior. It is written for veterinary students who have completed introductory pathology and are moving into clinical oncology rotations or advanced study.

The content spans the molecular mechanisms of carcinogenesis, the biologic distinctions between benign and malignant behavior, and the histologic classification systems used in veterinary diagnostic pathology. Specific tumor types and chemotherapeutic agents are excluded, as those topics are covered elsewhere in the curriculum. The emphasis here is on principles that apply across species, with attention to where veterinary consensus documents have standardized diagnostic approaches.

A working knowledge of the language of neoplasia is assumed: dysplasia, anaplasia, invasion, metastasis, grade, and stage are used throughout without redefinition. The reader should also be comfortable with basic molecular biology terms including oncogene, tumor suppressor gene, and growth factor receptor.

At a Glance

The Molecular Basis of Carcinogenesis

Cancer arises from the accumulation of genetic and epigenetic alterations that confer a selective growth advantage. These alterations affect genes that normally regulate cell division, programd cell death, DNA repair, and cell-cell interactions. The process is multistep, and the number and combination of alterations determine the biologic behavior of the resulting neoplasm.

Proto-oncogenes and Oncogenes

Proto-oncogenes are normal cellular genes that promote cell growth and division. When mutated or overexpressed, they become oncogenes that drive proliferation in a manner that is partially or fully independent of normal growth signals. The mutations are typically gain-of-function: a single altered allele can contribute to transformation. Examples include growth factor receptors, signal transduction proteins, and transcription factors.

The KIT receptor tyrosine kinase provides a well-characterized veterinary example. In canine cutaneous mast cell tumors, KIT protein overexpression and c-kit gene mutations have prognostic and predictive significance, as summarized in the Oncology-Pathology Working Group consensus on KIT expression and c-kit mutation. These alterations are also diagnostic markers, they influence tumor behavior and inform therapeutic decisions, illustrating how a single molecular pathway can be central to clinical oncology.

Tumor Suppressor Genes

Tumor suppressor genes normally restrain cell growth, promote apoptosis, or facilitate DNA repair. Loss-of-function mutations in these genes remove critical checkpoints, allowing damaged cells to survive and proliferate. Unlike oncogenes, both alleles typically must be inactivated for the effect to manifest, often through a combination of mutation, deletion, or epigenetic silencing.

The distinction between oncogenes and tumor suppressor genes is clinically relevant. Oncogene activation tends to produce constitutive signaling that may be targetable with specific inhibitors. Tumor suppressor loss is more difficult to reverse pharmacologically, and its consequences are often broader because these genes participate in multiple cellular pathways.

Genomic Instability and DNA Repair Defects

Cells with defective DNA repair mechanisms accumulate mutations at an accelerated rate. This genomic instability is a driver of carcinogenesis because it increases the probability that a cell will acquire the multiple alterations required for malignant behavior. Defects may be inherited or acquired, and they predispose to neoplasia across species.

Stages of Carcinogenesis

Carcinogenesis proceeds through three conceptual stages. Initiation is the initial genetic alteration in a cell, often caused by a mutagen that damages DNA. Initiated cells do not necessarily form tumors, they are primed but not committed. Promotion involves the selective expansion of initiated cells, often driven by growth factors, hormones, or chronic inflammation. Promoters are not mutagenic themselves but create an environment that favors proliferation of initiated cells. Progression is the final stage, in which additional genetic alterations accumulate and the neoplasm acquires increasingly malignant characteriztics, including invasion and metastatic capacity.

This framework has practical value. It explains why not all mutagen exposure leads to cancer, why latency periods can be long, and why chronic inflammation is a risk factor for neoplasia at many anatomic sites. It also underscores that carcinogenesis is a process, not a single event, and that intervention at any stage may alter the outcome.

Benign and Malignant Neoplasms

The distinction between benign and malignant neoplasms rests on biologic behavior instead of on any single histologic feature. Benign neoplasms are typically circumscribed, expand slowly, and do not invade surrounding tissues or metastasize. They may still cause morbidity through mass effect, hormone production, or obstruction. Malignant neoplasms invade adjacent tissues, have the capacity to metastasize, and frequently recur after incomplete excision.

Histologic features that support malignancy include cellular atypia, increased mitotic activity, necrosis, and invasion of surrounding structures. However, these features exist on a continuum, and some neoplasms show intermediate behavior. The clinical context, including anatomic location and completeness of excision, is essential for interpreting histologic findings.

Histologic Classification and Grading

Classification of neoplasms begins with identification of the cell of origin. Carcinomas arise from epithelium, sarcomas from mesenchyme, lymphomas from lymphoid cells, and melanocytic neoplasms from melanocytes. Within each category, further subclassification is based on differentiation patterns, architectural features, and immunohistochemical markers.

The Role of Immunohistochemistry

Immunohistochemistry (IHC) uses antibodies against lineage-specific proteins to identify the cell of origin when histomorphology is ambiguous. For example, the OPWG consensus on canine melanocytic neoplasms discusses how IHC markers support diagnosis when melanin pigment is absent or sparse. IHC is also used to assess proliferation rates, hormone receptor status, and the expression of prognostic markers.

Grading Systems and Consensus Recommendations

Histologic grading assigns a score based on features such as differentiation, mitotic count, and necrosis. The grade correlates with clinical outcome and guides treatment decisions. Veterinary grading systems are tumor-type specific, and several have been standardized through consensus processes.

The OPWG consensus on grading canine cutaneous mast cell tumors provides a critical review of available grading schemes and offers recommendations for their clinical interpretation. Similarly, the OPWG consensus on soft tissue sarcomas in dogs addresses the challenges of classifying a heterogeneous group of mesenchymal neoplasms with variable biologic behavior. These documents emphasize that grading is most useful when applied consistently and interpreted in the context of other clinical findings.

Lymphoma Classification

Lymphoma classification has evolved from morphology-based systems to incorporate immunophenotype and molecular features. The OPWG consensus on primary nodal lymphomas in dogs concludes that histopathology with immunohistochemistry is required for complete diagnosis and classification, and that molecular clonality testing should not replace immunophenotyping. This consensus reflects a broader trend in veterinary oncology toward standardized, evidence-based diagnostic approaches.

Challenges in Veterinary Diagnostic Pathology

Several factors complicate the diagnosis and classification of neoplasms in veterinary patients. Tumor heterogeneity means that a single biopsy may not represent the entire neoplasm. Sampling error, crush artifact, and inadequate tissue can limit diagnostic accuracy. The Davis-Thompson Foundation veterinary pathology resources provide educational case material that helps pathologists and students recognize these challenges and develop diagnostic skills.

The MSD Veterinary Manual offers species-specific guidance on neoplastic diseases, including clinical presentation and diagnostic approach. These resources complement consensus documents by providing practical, accessible information for practitioners. The historical observation that microscopic tumor diagnosis was underutilized in veterinary practice, noted in a review of veterinary oncology and pathology cooperation, remains relevant: accurate classification depends on adequate biopsy and histologic examination, and this principle has not changed with advances in molecular diagnostics.

Specimen Handling and Diagnostic Workflow

The diagnostic sequence begins before the biopsy instrument touches the patient. Sample quality determines whether histologic classification, grading, and ancillary testing are possible at all. For cutaneous and subcutaneous masses, excisional biopsy with clean margins is ideal when the mass is small and mobile. Incisional biopsy is preferred for large, fixed, or anatomically complex masses where surgical planning depends on histologic diagnosis. Needle core biopsy offers a compromise when incisional biopsy is impractical, but the smaller sample increases the risk of nondiagnostic or nonrepresentative tissue.

Fixation volume and timing matter. Formalin should be at least ten times the tissue volume, and samples should be sectioned thinly enough to permit penetration. Large specimens should be bread-loafed before fixation. Decalcification of osseous samples can destroy antigenicity for immunohistochemistry, so coordinate with the laboratory when bone is included. Cytologic preparations from fine-needle aspiration should be air-dried and stained with Romanowsky-type stains, parallel formalin-fixed and fresh samples may be required if flow cytometry or molecular testing is anticipated.

The Davis-Thompson Foundation veterinary pathology resources provide case material and diagnostic teaching collections that illustrate the range of morphologic presentations encountered in practice. For primary nodal lymphomas, the Oncology-Pathology Working Group consensus on canine nodal lymphoma diagnosis states that histopathology with immunohistochemistry is required for complete diagnosis and classification, and that cytology alone is insufficient for subclassification.

Histologic Assessment: What the Pathologist Evaluates

Histologic classification rests on identifying the tissue of origin and the degree of differentiation. The pathologist evaluates architecture, cytologic features, stromal reaction, and invasion patterns. Mitotic count remains one of the most reproducible and prognostically meaningful parameters across tumor types. It should be reported as the number of mitoses per 2.37 mm² (ten high-power fields in most modern microscopes) or per a defined area, and the counting method should be stated explicitly.

Margin assessment requires inking of surgical borders before sectioning. A margin is reported as complete, close, or incomplete based on the distance between neoplastic cells and the inked edge. For soft tissue sarcomas, the Brazilian Association of Veterinary Oncology consensus on canine soft tissue sarcoma emphasizes that these tumors have poorly defined margins, are invasive, and are prone to local recurrence despite apparent complete excision. Histologic grade, also margin status, drives prognosis and adjuvant therapy decisions.

Grading Systems in Practice

Grading translates histologic features into a prognostic category. The most widely used systems in veterinary oncology are the Patnaik and Kiupel systems for canine cutaneous mast cell tumors and the system described by Kuntz and colleagues for soft tissue sarcomas. The Oncology-Pathology Working Group consensus on grading canine cutaneous mast cell tumors recommends that both grades be reported when possible, because they capture different information. Patnaik grade is based on architectural and cytologic features, while Kiupel grade is a two-tier system based on mitotic count, multinucleation, bizarre nuclei, and karyomegaly. The two systems can disagree, and the working group advises that Kiupel grade may better identify biologically aggressive tumors.

For soft tissue sarcomas, grading incorporates differentiation score, mitotic count, and percentage of tumor necrosis. The consensus document from the Brazilian Association of Veterinary Oncology notes that diagnosis and prognosis determination can be challenging due to the diversity of subtypes, and that standardization of procedures improves comprehension of this tumor group.

Immunohistochemistry and Ancillary Testing

Immunohistochemistry confirms lineage when morphology is ambiguous. For melanocytic neoplasms, the Oncology-Pathology Working Group consensus on canine melanocytic neoplasms recommends a panel approach because no single marker is both sensitive and specific. Melan A and PNL2 are sensitive markers, while S100 is sensitive but less specific. Cytokeratin and vimentin help distinguish epithelial from mesenchymal origin. For round cell tumors, CD3 and CD20 or Pax5 distinguish T-cell from B-cell lymphomas, and CD18 or CD45 confirm leukocyte origin.

KIT immunostaining in canine mast cell tumors has both prognostic and predictive value. The Oncology-Pathology Working Group consensus on KIT expression and c-kit mutation describes three staining patterns: membranous (pattern 1), focal or stippled cytoplasmic (pattern 2), and diffuse cytoplasmic (pattern 3). Patterns 2 and 3 correlate with internal tandem duplication mutations in exon 11 of c-kit and are associated with increased risk of recurrence and reduced survival. Tumors with these patterns may respond to tyrosine kinase inhibitors, making the test both prognostic and predictive.

Flow cytometry is the preferred method for immunophenotyping when a fresh sample is available, particularly for lymphomas. The OPWG consensus on canine nodal lymphoma states that immunohistochemistry and flow cytometry are the most reliable methods of immunophenotyping, though neither is clearly superior. Molecular clonality testing for antigen receptor gene rearrangement should not replace immunophenotyping for classification.

Species and Setting Considerations

The correct diagnostic approach changes with species, tumor location, and available resources. In dogs, histologic grading systems are well validated for mast cell tumors and soft tissue sarcomas. In cats, mast cell tumors behave differently: the splenic and visceral forms are more common, and cutaneous mast cell tumors in cats are often less aggressive than their canine counterparts. Grading systems developed for dogs should not be applied to cats without caution.

In production animals, the diagnostic workup is constrained by economic factors and regulatory requirements. The WOAH terrestrial animal health standards address disease surveillance and reporting obligations that may apply when neoplasia mimics or coexists with notifiable diseases. The MSD Veterinary Manual provides species-specific guidance on tumor behavior and diagnostic approaches for food animals, where a presumptive diagnosis based on signalment and gross appearance may be the practical endpoint.

In equine practice, sarcoids are the most common cutaneous neoplasm and are diagnosed clinically in most cases, with biopsy reserved for atypical presentations. The pathologist should be informed of the clinical suspicion because sarcoid histology can be subtle and is easily mistaken for other fibrotic lesions.

Documentation and Reporting

The pathology report should communicate information that changes clinical decisions. Minimum content includes gross description, sample adequacy statement, histologic diagnosis, grade where applicable, margin status, mitotic count, and results of ancillary testing. The report should state which grading system was used and acknowledge when a tumor does not fit neatly into an established category.

The OPWG consensus on canine melanocytic neoplasms recommends that reports for melanocytic tumors include anatomic site, growth phase, mitotic count, and presence or absence of ulceration, because these features carry independent prognostic information. For oral melanocytic neoplasms, the same document notes that these tumors are consistently more aggressive than cutaneous forms, and the report should reflect that site-specific behavior.

When the pathologist and clinician disagree on interpretation, direct communication is warranted. The historical concern that microscopic tumor diagnosis was practiced at too low a scale, raised by Misdorp in his review of veterinary oncology practice, remains relevant. A biopsy that cannot change management should be questioned, but a biopsy that might alter prognosis, margin assessment, or adjuvant therapy decisions should be pursued even when the clinical picture seems clear.

Recognized Complications and Failure Modes

The most consequential failure in veterinary oncologic pathology is misclassification of tumor type or grade, which directly alters therapeutic decisions and prognostic communication. For soft tissue sarcomas, the consensus of the Brazilian Association of Veterinary Oncology emphasizes that these tumors have poorly defined margins, making them invasive and prone to local recurrence, yet they metastasise at low rates and respond poorly to chemotherapy. A pathologist who mislabels a high-grade sarcoma as benign on the basis of a small incisional biopsy has committed a sampling error, not an interpretive one. The corrective action is to report the limitation explicitly and recommend excisional biopsy for definitive grading.

Mast cell tumors present a distinct failure mode: grading discordance between cytologic and histologic samples. The Oncology-Pathology Working Group consensus on canine cutaneous mast cell tumors notes that cytologic grading is discussed but histologic grading remains the primary determinant of prognosis. A less experienced clinician may initiate treatment based on cytologic grade alone, missing the higher-grade component present in the excised tissue. The discriminating check is to compare the mitotic count between the cytology report and the final histopathology report, a discrepancy of more than two mitoses per 10 high-power fields warrants re-review of both samples.

Lymphoma classification fails most often when immunophenotyping is omitted or when molecular clonality testing is used as a substitute. The OPWG consensus on primary nodal lymphomas in dogs states that histopathology with immunohistochemistry is required for complete diagnosis and classification, and that molecular clonality testing should not be used in favour of immunophenotyping assays. Detection of this error is straightforward: a lymphoma report that lacks a B-cell or T-cell designation is incomplete and should be returned to the laboratory for additional staining.

Common Errors and Corrective Actions

Students and early-career clinicians frequently overinterpret the term "benign" in a histopathology report as equivalent to "cured." For melanocytic neoplasms, the OPWG consensus on canine melanocytic neoplasms distinguishes cutaneous from oral and lip tumors because their biologic behavior differs substantially, and histopathologic prognostication requires site-specific criteria. The corrective action is to read the report in full, including the microscopic description, before communicating prognosis to the owner.

A second recurring error is the assumption that a single grading system applies across species and tumor types. The OPWG documents for mast cell tumors, lymphomas, and melanocytic neoplasms each specify their own criteria, and the Brazilian soft tissue sarcoma consensus likewise defines its own histomorphologic features and immunohistochemical markers. Applying the Patnaik mast cell tumor grade to a soft tissue sarcoma is a category error. The corrective action is to verify that the grading system named in the report matches the tumor type and the species.

A third error is neglecting to integrate KIT expression and c-kit mutation status for mast cell tumors. The OPWG consensus on KIT protein expression and c-kit gene mutation states that these tests provide prognostic and predictive significance, but they are complementary to histologic grading, not replacements for it. A clinician who orders KIT testing but ignores the mitotic count has assembled an incomplete prognostic picture.

Limitations of Current Evidence

The evidence base for veterinary oncologic pathology is uneven across tumor types and species. The OPWG consensus documents are explicit that they represent the opinions of the working group and do not constitute formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society. This caveat reflects genuine uncertainty in areas where prospective validation studies are lacking.

Expert opinion still differs on the clinical weight assigned to mitotic count versus histologic grade in specific contexts. For mast cell tumors, the OPWG consensus acknowledges that grading systems have limitations and that mitotic count carries independent prognostic information. For lymphomas, the OPWG consensus identifies knowledge gaps and recommends future study, particularly regarding emerging molecular tests, which should be restricted to investigational settings until validated.

The Brazilian soft tissue sarcoma consensus similarly notes that diagnosis and prognosis determination can be challenging due to the diversity of subtypes. Standardization efforts by international organizations such as the Oncology Pathology Working Group aim to reduce this variability, but the diversity of histologic patterns means that inter-pathologist agreement will never be perfect.

Referral and Escalation Criteria

Referral to a specialist pathologist or oncology service is warranted when the histologic diagnosis conflicts with clinical behavior, when the tumor is of a subtype known to have high inter-observer variability, or when the treatment decision hinges on a grade that the submitting pathologist has flagged as uncertain. The Davis-Thompson Foundation provides educational pathology collections and case material that can support second-opinion review and continuing education.

Laboratory involvement is appropriate when ancillary testing is required but not available at the primary laboratory. The OPWG lymphoma consensus states that immunohistochemistry and flow cytometry are the most reliable methods of immunophenotyping, though neither is clearly superior. If the primary laboratory cannot perform flow cytometry, referral to a laboratory that can is indicated before treatment initiation.

Regulatory reporting obligations vary by jurisdiction and species. The World Organization for Animal Health terrestrial animal health standards address surveillance and trade-related disease control, and neoplasms with suspected infectious aetiology, such as feline leukemia virus-associated lymphoma, may warrant reporting under regional frameworks. The American Veterinary Medical Association practice resources provide guidance on professional obligations, but specific reporting requirements are jurisdiction-specific and must be verified locally.

Frequently Asked Questions

How Should I Prioritize Ancillary Testing When the Biopsy Sample Is Small or the Owner Has Limited Financial Resources?

When sample quantity or budget is constrained, histopathology with routine hematoxylin and eosin staining remains the diagnostic foundation. A complete histologic assessment should take priority over immunohistochemistry, because morphology alone often permits a working diagnosis and provisional grade. If immunohistochemistry is feasible, select one or two antibodies that directly influence treatment decisions, such as KIT expression in canine cutaneous mast cell tumors, instead of a broad diagnostic panel. The Oncology-Pathology Working Group consensus on KIT protein expression and c-kit gene mutation in canine mast cell tumors notes that KIT immunostaining provides prognostic information that can guide systemic therapy decisions. For melanocytic neoplasms, the OPWG consensus on canine melanocytic neoplasms recommends that when resources are limited, histologic features such as mitotic count and nuclear atypia should drive prognostication before ancillary testing is considered.

What Minimum Data Should My Histopathology Request Form Include to Maximize Diagnostic Yield?

The request form should state the patient signalment, lesion location, duration, gross dimensions, and whether the sample is incisional, excisional, or a punch biopsy. Include prior treatment, especially corticosteroids, because these alter lymphoid and mast cell morphology. Note whether the entire lesion was removed and whether surgical margins require assessment. The OPWG consensus on canine cutaneous mast cell tumor grading emphasizes that accurate grading depends on the pathologist knowing the tumor site and sample type, since these influence mitotic count interpretation and grade assignment. For lymph node samples, specify the node and whether it was aspirated or excised, because consensus guidance on primary nodal lymphomas in dogs requires histopathology with immunohistochemistry for complete classification, and the pathologist must know if the sample is adequate for that workflow.

How Do I Handle a Discrepancy Between the Histologic Grade and the Clinical Behavior of a Tumor?

A discrepancy should prompt a review of both the sample and the clinical record. First, confirm the biopsy was representative and not necrotic, crushed, or from the tumor periphery. Second, verify that the grading system used matches the tumor type and anatomic site, because grade criteria differ between entities. For soft tissue sarcomas, the Brazilian consensus report on canine soft tissue sarcomas notes that these tumors have poorly defined margins and low metastatic rates, so local recurrence may reflect incomplete excision instead of a grade error. Third, consider that a single mitotic count reflects one moment in tumor evolution. If clinical behavior diverges sharply from grade, request a second opinion from a veterinary pathologist with oncology focus. The Davis-Thompson Foundation offers slide consultation services that can support such reviews.

What Should I Document in the Medical Record Regarding Tumor Diagnosis and Staging?

Record the biopsy method, sample site, fixation details, and the date the sample was submitted. Document the full histopathology report verbatim or as an attached file, including grade, mitotic count, margin status, and immunohistochemical results. Note any discrepancy between your clinical suspicion and the histologic diagnosis, and record the discussion with the owner, including prognostic estimates and treatment options offered. The AVMA practice resources emphasize that medical records must support continuity of care and defend clinical decisions if they are later reviewed. For production animals, additional documentation may be required for food safety or trade purposes, and the WOAH terrestrial animal health standards outline surveillance and reporting expectations that may apply to certain neoplasms.

How Does the Diagnostic Approach Differ for a Cat or Horse Compared with a Dog?

The core histologic principles are identical across species, but tumor biology and grading systems differ. Canine grading schemes, such as those for mast cell tumors, do not transfer directly to feline mast cell tumors, which have different histologic patterns and clinical behavior. The MSD Veterinary Manual provides species-specific guidance on tumor behavior and diagnostic approaches. In horses, sarcoids and melanomas have clinical presentations that may not require biopsy when the diagnosis is obvious, but biopsy is still indicated when treatment is planned or when behavior is atypical. For cats, mammary tumors are more aggressive than in dogs, and histologic grading systems differ. Always confirm that the grading system you apply was validated for the species and anatomic site in question, and state this explicitly in the record.

How Should I Explain a Cancer Diagnosis and Prognosis to an Owner Without Causing Confusion or False Hope?

Use the histopathology report as the anchor for the conversation. Start with the diagnosis in plain terms, then explain the grade as a measure of expected behavior, not a guarantee. Distinguish between local recurrence risk and metastatic risk, because owners often conflate the two. For soft tissue sarcomas, the Brazilian consensus report notes that local recurrence is the primary concern while metastasis is uncommon, which allows a more measured discussion. Be explicit about what is known and what is uncertain, and avoid numeric survival claims that the report does not support. Offer a written summary of the discussion, including the next diagnostic step and the treatment options, and invite the owner to return with questions after they have had time to process the information.

Related Clinical & Scientific Guides

• Hypersensitivity Reactions: Types and Mechanisms
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Monitoring Fluid Therapy in Critically Ill Veterinary Patients

References and Further Reading

• Canine cutaneous and subcutaneous soft tissue sarcoma in dogs: a consensus report from the Brazilian association of veterinary oncology.. 2026.
• Value, Limitations, and Recommendations for Grading of Canine Cutaneous Mast Cell Tumors: A Consensus of the Oncology-Pathology Working Group.. 2021.
• Diagnosis and Classification of Primary Nodal Lymphomas in Dogs: A Consensus of the Oncology-Pathology Working Group.. 2025.
• [[Oncology, pathology and companion animal practice].](https://pubmed.ncbi.nlm.nih.gov/7992306/). 1994.
• Diagnosis and histopathologic prognostication of canine melanocytic neoplasms: A consensus of the Oncology-Pathology Working Group.. 2022.
• Prognostic and predictive significance of KIT protein expression and c-kit gene mutation in canine cutaneous mast cell tumors: A consensus of the Oncology-Pathology Working Group.. 2019.
• Davis-Thompson Foundation Veterinary Pathology Resources. Davis-Thompson Foundation.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Edema and Shock: Pathophysiologic Mechanisms
• Cell Injury Mechanisms and Morphologic Patterns
• Environmental Toxins and Mechanisms of Cellular Injury
• Genetic Diseases in Animals: Mechanisms and Examples
• Autoimmunity: Mechanisms and Veterinary Examples

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.